
The Diaxonhit group is a French fully integrated leader in the field of in-vitro diagnostic with expertise ranging from discovery to the commercialization of specialty diagnostic products.
As a result of the acquisition of InGen BioSciences by Exonhit, the new group benefits from the complementary capabilities derived from both companies’ business models, activities and know-how.
Diaxonhit immediately focus its efforts on the continued development of its distribution activities, leveraging the sales organization that is already in place, and accelerating the development of its high added value proprietary innovative diagnostic products.
Diaxonhit owns a broadened and diversified portfolio of proprietary diagnostic products in three specialty areas : transplantation, infectious diseases and cancer diagnosis.
The group is currently marketing its first proprietary test, TQS® (Tetanus Quick Stick), used in emergency clinics for the evaluation of the protective status of a patient against tetanus. Additionally, Diaxonhit continues the developement of its innovative molecular diagnostics products.
The group has a balanced development strategy, with in-house research programs and strategic collaborations.
Contact
65 Boulevard Masséna
F-75013 PARIS – FRANCE
Tel: +33 (0) 1 53 94 77 00
Fax: +33 (0) 1 53 94 77 07
Email: Pleaseforward@diaxonhit.com
Web: www.diaxonhit.com